Particle platforms for cancer immunotherapy

Rita Elena Serda Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA Abstract: Elevated understanding and respect for the relevance of the immune system in cancer development and therapy has led to increased development of immunotherapeutic regimens that target ex...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Serda RE
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2013
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/50b53c5cec664e34b62b9f7b6d4e5b68
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:50b53c5cec664e34b62b9f7b6d4e5b68
record_format	dspace
spelling	oai:doaj.org-article:50b53c5cec664e34b62b9f7b6d4e5b682021-12-02T07:15:35ZParticle platforms for cancer immunotherapy1176-91141178-2013https://doaj.org/article/50b53c5cec664e34b62b9f7b6d4e5b682013-04-01T00:00:00Zhttp://www.dovepress.com/particle-platforms-for-cancer-immunotherapy-a12908https://doaj.org/toc/1176-9114https://doaj.org/toc/1178-2013Rita Elena Serda Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA Abstract: Elevated understanding and respect for the relevance of the immune system in cancer development and therapy has led to increased development of immunotherapeutic regimens that target existing cancer cells and provide long-term immune surveillance and protection from cancer recurrence. This review discusses using particles as immune adjuvants to create vaccines and to augment the anticancer effects of conventional chemotherapeutics. Several particle prototypes are presented, including liposomes, polymer nanoparticles, and porous silicon microparticles, the latter existing as either single- or multiparticle platforms. The benefits of using particles include immune-cell targeting, codelivery of antigens and immunomodulatory agents, and sustained release of the therapeutic payload. Nanotherapeutic-based activation of the immune system is dependent on both intrinsic particle characteristics and on the immunomodulatory cargo, which may include danger signals known as pathogen-associated molecular patterns and cytokines for effector-cell activation. Keywords: adjuvant, particle, immunotherapy, dendritic cell, cancer, vaccineSerda REDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2013, Iss default, Pp 1683-1696 (2013)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Serda RE Particle platforms for cancer immunotherapy
description	Rita Elena Serda Department of Nanomedicine, The Methodist Hospital Research Institute, Houston, TX, USA Abstract: Elevated understanding and respect for the relevance of the immune system in cancer development and therapy has led to increased development of immunotherapeutic regimens that target existing cancer cells and provide long-term immune surveillance and protection from cancer recurrence. This review discusses using particles as immune adjuvants to create vaccines and to augment the anticancer effects of conventional chemotherapeutics. Several particle prototypes are presented, including liposomes, polymer nanoparticles, and porous silicon microparticles, the latter existing as either single- or multiparticle platforms. The benefits of using particles include immune-cell targeting, codelivery of antigens and immunomodulatory agents, and sustained release of the therapeutic payload. Nanotherapeutic-based activation of the immune system is dependent on both intrinsic particle characteristics and on the immunomodulatory cargo, which may include danger signals known as pathogen-associated molecular patterns and cytokines for effector-cell activation. Keywords: adjuvant, particle, immunotherapy, dendritic cell, cancer, vaccine
format	article
author	Serda RE
author_facet	Serda RE
author_sort	Serda RE
title	Particle platforms for cancer immunotherapy
title_short	Particle platforms for cancer immunotherapy
title_full	Particle platforms for cancer immunotherapy
title_fullStr	Particle platforms for cancer immunotherapy
title_full_unstemmed	Particle platforms for cancer immunotherapy
title_sort	particle platforms for cancer immunotherapy
publisher	Dove Medical Press
publishDate	2013
url	https://doaj.org/article/50b53c5cec664e34b62b9f7b6d4e5b68
work_keys_str_mv	AT serdare particleplatformsforcancerimmunotherapy
_version_	1718399515303608320

Particle platforms for cancer immunotherapy

Ejemplares similares